Medtronic launches VitalFlow™, a new Extracorporeal Membrane Oxygenation (ECMO) system

Medtronic plc, the global leader in medical technology, today announced the launch of a new ECMO system called VitalFlow™, which is a configurable one-system ECMO solution, built on simplicity and performance. The VitalFlow™ ECMO System bridges the gap between bedside care and intra-hospital transport, offering physicians and clinicians an easier, smarter ECMO experience.

The VitalFlow™ technology is the most innovative technology to-date from the Medtronic acquisition of MC3 Cardiopulmonary, which closed in March 2024. The acquisition marked the culmination of an eight-year partnership and distribution agreement with the Medtronic Cardiac Surgery business resulting in the introduction of seven new ECMO products in seven years. Prior to the acquisition, MC3 Cardiopulmonary consistently developed and manufactured differentiated, high-quality ECMO products, which were exclusively distributed by Medtronic. These products, including catheters and oxygenators, are distinguished by their ability to simplify therapy and enhance ease of use. Additionally, the partnership has reliably supplied these long-term indicated products throughout the COVID pandemic and beyond.

"The launch of this technology further underscores Medtronic's unwavering dedication to developing life-restoring medical devices that address both acute and chronic cardiopulmonary clinical needs, and demonstrates our sustained commitment to this vital field," said Karim Bandali, Ph.D., president of the Cardiac Surgery business within the Cardiovascular portfolio at Medtronic. "This announcement builds on our recent acquisitions, including a Viant Medical contract manufacturing site and the Penditure™ Left Atrial Appendage Exclusion System. Clinicians can continue to expect a global cadence of bold and unique innovations, focused on addressing diverse clinician needs while enhancing our ability to meet the needs of all cardiac surgery patients."

These latest acquisitions enable Medtronic to offer the most robust Cardiac Surgery portfolio available today. As the only business that serves the whole heart care team of cardiac surgeons and perfusionists, Medtronic is committed to innovating in heart valves, surgical ablation, left atrial appendage management (LAAM), revascularization, perfusion, cannulation technologies, and ECMO therapies to advance treatment options, providing distinct benefits to physicians and clinicians, enabling them to focus on the holistic lifetime management of patients.

The VitalFlow system brings a critical solution for ECMO
The user-friendly VitalFlow system features a large, intuitive touch screen that centralizes real-time performance data, offers configurability, and is built for long-term performance incorporating the proven Medtronic Nautilus™ ECMO oxygenator design.

"In gathering feedback from hundreds of clinicians with diverse ECMO specialties, we were able to design the VitalFlow system to address the most pressing unmet needs of simplicity, configurability and performance in an ECMO system," said Bandali. "The simplicity of the VitalFlow system allows multiple users with varying levels of comfort to serve patients confidently and efficiently. It is easily portable from various departments within the hospital setting, with durable and reliable performance."

The VitalFlow system and other Medtronic ECMO technologies will be featured at the upcoming 35th Annual Conference of the Extracorporeal Life Support Organization (ELSO) from September 29 - October 1 in Detroit where Medtronic will also hold two ECMO Workshops to facilitate hands-on engagement and learnings for the company's ECMO technologies. The workshops will focus on VitalFlow system simulations, and cannulation with the Crescent™ RA pediatric cannula, the Bio Medicus™ LS cannula, and the Crescent™ cannula.

"Clinicians in the ECMO space have evolving needs," said Pieter Kappetein, Ph.D., M.D., chief medical officer, Cardiac Surgery, Medtronic. "With patients' diseases becoming more complex, there is a growing demand for innovative solutions and comprehensive commitments across multiple disease states. Clinicians expect more from Medtronic and we are uniquely positioned to meet these needs to advance treatment options to better serve their patients."

About ECMO
ECMO uses a pump and oxygenator outside of the body to take over the work of the heart and lungs to restore health and extend life to critically ill patients who might otherwise expire. ECMO is most often used for life-threatening heart or lung failure to allow the heart and/or lung to rest and heal. It's also used as a bridge option to heart or lung transplantation or to further treatment such as heart assist device or left ventricular assist device (LVAD).

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Becky Dvorak
Public Relations
+1-612-309-7149

Ryan Weispfenning
Investor Relations
+1-763-505-4626

Public link

Please use the above public link if you want to share this noodl on another website.